For more than 15 years, COPAXONE has been studied in clinical trials and prescribed to patients as an FDA-approved self-administered injectable treatment for reducing the frequency of relapses in patients diagnosed with relapsing-remitting multiple sclerosis (RRMS). However, similar to other multiple sclerosis (MS) disease-modifying therapies (DMTs), nearly all studies of COPAXONE primarily assess such clinical endpoints as improvement in the clinician-administered Expanded Disability Status Scale (EDSS) or a reduction in lesion activity as measured by magnetic resonance imaging (MRI).
By contrast, comparatively little is known about the real-world experiences and value of COPAXONE from the perspective of the individual actually using the product: the MS patient. Understanding this perspective complements knowledge derived from the clinician and facilitates new learning about COPAXONE usage and future prospects. For example:
- Who are COPAXONE users? What characteristics define them?
- What attitudes do they express? What are their experiences on COPAXONE?
- How long do they remain on COPAXONE? Why do they discontinue?
- Is COPAXONE appropriately priced given its perceived impact in the real world?
Answers to these and other questions derived from shared real-world patient experiences with COPAXONE on PatientsLikeMe constitute the focus of this report.
Are you ready to tune into the growing and driving force behind treatment selection—the patient?
To purchase this report or for more information, call (617) 229-6706 or email us at email@example.com.
Purchase price: $1,800.00 USD.